| Name |
CAS |
MF |
MW |
Single-letter sequence |
Three-letter sequence |
Number of AA |
Type |
Inquiry |
| TPP-1 |
|
C107H150N34O32S2 |
2488.67 |
H2N-SGQYASYHCWCWRDPGRSGGSK-OH |
H2N-Ser-Gly-Gln-Tyr-Ala-Ser-Tyr-His-Cys-Trp-Cys-Trp-Arg-Asp-Pro-Gly-Arg-Ser-Gly-Gly-Ser-Lys-OH |
22 |
PD-L1–targeting peptide |
|
| HAC-V |
|
C49H80N14O14 |
1089.24 |
H2N-HVVHEGTVVI-OH |
H2N-His-Val-Val-His-Glu-Gly-Thr-Val-Val-Ile-OH |
10 |
PD-L1–targeting peptide |
|
| DPPA-1 |
|
C70H98N20O21 |
1555.65 |
H2N-nyskptdrqyhf-OH |
H2N-DAsn-DTyr-DSer-DLys-DPro-DThr-DAsp-DArg-DGln-DTyr-DHis-DPhe-OH |
12 |
PD-L1–targeting peptide |
|
| AP-1 |
|
C107H150N34O32S2 |
2488.67 |
H2N-SGQYASYHCWCWRDPGRSGGSK-OH |
H2N-Ser-Gly-Gln-Tyr-Ala-Ser-Tyr-His-Cys-Trp-Cys-Trp-Arg-Asp-Pro-Gly-Arg-Ser-Gly-Gly-Ser-Lys-OH |
22 |
APN-targeting peptide |
|
| EP-1 |
|
C49H80N14O14 |
1089.24 |
H2N-HVVHEGTVVI-OH |
H2N-His-Val-Val-His-Glu-Gly-Thr-Val-Val-Ile-OH |
10 |
EpCAM-targeting peptide |
|
| GSC-IC2 |
|
C51H58N8O11 |
959.05 |
H2N–AWEFYFP–OH |
H2N–Ala–Trp–Glu–Phe–Tyr–Phe–Pro–OH |
7 |
GBC tumor–targeting peptide |
|
| STP |
|
C70H98N20O21 |
1555.65 |
H2N-nyskptdrqyhf-OH |
H2N-DAsn-DTyr-DSer-DLys-DPro-DThr-DAsp-DArg-DGln-DTyr-DHis-DPhe-OH |
12 |
|
|
| RES-701-1 |
151308-34-8 |
C103H115N23O23 |
2043.19 |
Cyclo(-GNWHGTAPD)WFFNYYW |
Cyclo(-Gly-Asn-Trp-His-Gly-Thr-Ala-Pro-Asp)-Trp-Phe-Phe-Asn-Tyr-Tyr-Trp-OH |
16 |
|
|
| SYLQDSVPDSFQD |
320341-56-8 |
C65H93N15O26 |
1500.52 |
H2N-SYLQDSVPDSFQD-OH |
H2N-Ser-Tyr-Leu-Gln-Asp-Ser-Val-Pro-Asp-Ser-Phe-Gln-Asp-OH |
13 |
|
|
| Thrombospondin-1 (TSP-1)–derived CD36 Binding Motif |
138849-26-0 |
C20H34N6O9S2 |
566.65 |
H2N-CSVTCG-OH |
H2N-Cys-Ser-Val-Thr-Cys-Gly-OH |
6 |
|
|
| ELT |
|
C60H90N12O19S2 |
1347.56 |
H2N-ELTVMGYYPGMS-OH |
H2N-Glu-Leu-Thr-Val-Met-Gly-Tyr-Tyr-Pro-Gly-Met-Ser-OH |
12 |
Gastric cancer–targeting peptide |
|
| GLP-1(28-36)amide |
1225021-13-5 |
C54H85N15O9 |
1088.35 |
H2N-FIAWLVKGR-CONH2 |
H2N-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-CONH2 |
9 |
Mitochondria-targeting peptide |
|
| CBO-P11 |
612096-46-5 |
C94H145N29O25S |
2113.4 |
Cyclo(RIKPHQGQHIGEDFPQIM) |
Cyclo(Asp-Phe-Pro-Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly-Glu) |
18 |
Tumor Angiogenesis-targeting ligands |
|
| TAT-GluN2BCTM |
1587742-50-4 |
C224H374N86O54 |
5135.91 |
H2N-YGRKKRRQRRRKKNRNKLRRQHSYKFERQKILDQRFFE-OH |
H2N-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Lys-Asn-Arg-Asn-Lys-Leu-Arg-Arg-Gln-His-Ser-Tyr-Lys-Phe-Glu-Arg-Gln-Lys-Ile-Leu-Asp-Gln-Arg-Phe-Phe-Glu-OH |
38 |
DAPK1–targeting peptide |
|
| KGYY15 |
1690215-31-6 |
C84H129N21O22S1 |
1815.93 |
H2N-VLQWAKKGYYTMKSN-OH |
H2N-Val-Leu-Gln-Trp-Ala-Lys-Lys-Gly-Tyr-Tyr-Thr-Met-Lys-Ser-Asn-OH |
15 |
CD40–targeting peptide |
|
| TPP-1 |
|
C107H150N34O32S2 |
2488.67 |
H2N-SGQYASYHCWCWRDPGRSGGSK-OH |
H2N-Ser-Gly-Gln-Tyr-Ala-Ser-Tyr-His-Cys-Trp-Cys-Trp-Arg-Asp-Pro-Gly-Arg-Ser-Gly-Gly-Ser-Lys-OH |
22 |
PD-L1–targeting peptide |
|
| HKP2201 |
|
C77H101N21O20 |
1640.75 |
H2N–WHRSYYTWNLNT–OH |
H2N–Trp–His–Arg–Ser–Tyr–Tyr–Thr–Trp–Asn–Leu–Asn–Thr–OH |
12 |
PD-L1–targeting peptide |
|
| EDIKPKTSLAFR |
|
C63H105N17O19 |
1404.61 |
H2N-EDIKPKTSLAFR-OH |
H2N-Glu-Asp-Ile-Lys-Pro-Lys-Thr-Ser-Leu-Ala-Phe-Arg-OH |
12 |
CEN-1 human nasopharyngeal carcinoma-targeting ligands |
|
| 123B9 |
2225868-19-7 |
C58H82ClFN12O20 |
1321.79 |
{2-(3-chloro-4-fluorophenoxy)acetic acid}-SAYPDSVP-Nle-Hsr-S-NH2 |
{2-(3-chloro-4-fluorophenoxy)acetic acid}-Ser-Ala-Tyr-Pro-Asp-Ser-Val-Pro-Nle-Hsr-Ser-NH2 |
11 |
EphA2 agonist |
|
| C7 |
2159055-74-8 |
C62H90N18O16S1 |
1375.57 |
H2N-MHTAPGWGYRLS-OH |
H2N-Met-His-Thr-Ala-Pro-Gly-Trp-Gly-Tyr-Arg-Leu-Ser-OH |
12 |
FRα-targeting peptide |
|
